A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder

• Published in: The American journal of psychiatry Vol. 158; no. 5; pp. 765 - 774
• Main Authors: Conley, Robert R., Mahmoud, Ramy
• Format: Journal Article
• Language: English
• Published: Washington, DC American Psychiatric Publishing 01.05.2001; American Psychiatric Association
• Subjects: Adult; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Basal Ganglia Diseases - chemically induced; Basal Ganglia Diseases - epidemiology; Benzodiazepines; Biological and medical sciences; Clinical trials; Double blind randomized trials; Double-Blind Method; Drug Administration Schedule; Drug therapy; Female; Humans; Male; Medical sciences; Neuropharmacology; Olanzapine; Pharmacology. Drug treatments; Pirenzepine - adverse effects; Pirenzepine - analogs & derivatives; Pirenzepine - therapeutic use; Psychiatric Status Rating Scales - statistics & numerical data; Psychiatry; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Psychotic Disorders - diagnosis; Psychotic Disorders - drug therapy; Psychotic Disorders - psychology; Risperidone; Risperidone - adverse effects; Risperidone - therapeutic use; Safety; Schizoaffective disorder; Schizophrenia; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Schizophrenic Psychology; Treatment Outcome; Weight Gain - drug effects; Human; Schizoaffective psychosis; Olanzapine; Neuroleptic; Psychotropic; Dopamine receptor; Toxicity; Dopamine antagonist; Serotonin antagonist; Treatment efficiency; Schizophrenia; Serotonine receptor; Dose activity relation; Psychosis; Chemotherapy; Treatment; Follow up study; Atypical; Antagonist; Risperidone; Comparative study

OBJECTIVE: The safety and efficacy of risperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in clinical practice. METHOD: Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg day of...